High Tech Pharm Co. Ltd (106190) - Cash Flow Conversion Efficiency
Based on the latest financial reports, High Tech Pharm Co. Ltd (106190) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.60 Billion ≈ $4.47 Million USD) by net assets (₩126.99 Billion ≈ $86.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 106190 stock market capitalisation for the company's overall valuation and market capitalisation.
High Tech Pharm Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how High Tech Pharm Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
High Tech Pharm Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of High Tech Pharm Co. Ltd ranked by their cash flow conversion efficiency. Explore how high is High Tech Pharm Co. Ltd's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guru Organic Energy Corp
TO:GURU
|
-0.007x |
|
SRV Group plc
HE:SRV1V
|
0.076x |
|
Sepeda Bersama Indonesia Tbk PT
JK:BIKE
|
-0.079x |
|
Spirit Technology Solutions Ltd
AU:ST1
|
-0.027x |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
-0.011x |
|
Klingon Aerospace Inc
TW:1529
|
-0.026x |
|
Trinity Precision Technology Co Ltd
TWO:4534
|
-0.019x |
|
ULMA Construccion Polska SA
WAR:ULM
|
-0.004x |
Annual Cash Flow Conversion Efficiency for High Tech Pharm Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of High Tech Pharm Co. Ltd from 2014 to 2024. View 106190 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩119.74 Billion ≈ $81.14 Million |
₩14.69 Billion ≈ $9.96 Million |
0.123x | +351.33% |
| 2023-12-31 | ₩106.99 Billion ≈ $72.51 Million |
₩2.91 Billion ≈ $1.97 Million |
0.027x | +173.37% |
| 2022-12-31 | ₩99.94 Billion ≈ $67.73 Million |
₩-3.70 Billion ≈ $-2.51 Million |
-0.037x | -150.21% |
| 2021-12-31 | ₩93.88 Billion ≈ $63.62 Million |
₩6.93 Billion ≈ $4.69 Million |
0.074x | +191.29% |
| 2020-12-31 | ₩95.14 Billion ≈ $64.48 Million |
₩-7.69 Billion ≈ $-5.21 Million |
-0.081x | -420.83% |
| 2019-12-31 | ₩98.58 Billion ≈ $66.81 Million |
₩2.48 Billion ≈ $1.68 Million |
0.025x | -51.59% |
| 2018-12-31 | ₩103.35 Billion ≈ $70.04 Million |
₩5.38 Billion ≈ $3.65 Million |
0.052x | -2.44% |
| 2017-12-31 | ₩102.19 Billion ≈ $69.26 Million |
₩5.45 Billion ≈ $3.69 Million |
0.053x | +272.82% |
| 2016-12-31 | ₩101.18 Billion ≈ $68.57 Million |
₩1.45 Billion ≈ $981.14K |
0.014x | -89.06% |
| 2015-12-31 | ₩97.20 Billion ≈ $65.87 Million |
₩12.71 Billion ≈ $8.61 Million |
0.131x | +18.32% |
| 2014-12-31 | ₩92.06 Billion ≈ $62.39 Million |
₩10.17 Billion ≈ $6.89 Million |
0.110x | -- |
About High Tech Pharm Co. Ltd
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.